BioCentury
ARTICLE | Clinical News

Selecta's gout combo lacks longer-term efficacy in Phase II trial

November 10, 2017 9:26 PM UTC

Selecta Biosciences Inc. (NASDAQ:SELB) reported updated data from an open-label, U.S. Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110), a nanoparticle encapsulating the immunomodulator rapamycin.

Selecta reported 20-week data from 79 evaluable patients among 8 of the study's 11 ongoing or planned cohorts. Among 4 cohorts receiving 2 middle doses of SVP-Rapamycin -- 0.08 or 0.1 mg/kg -- and either of 2 doses of pegsiticase, Selecta said a majority of patients showed clinical activity through week 12. The company said half of those patients maintained clinical activity through week 20 in the 0.1 mg/kg group; the company did not respond to an inquiry about clinical activity in the 0.08 mg/kg group. The study tested regimens of 0.2 and 0.4 mg/kg pegsiticase plus 0.05, 0.08, 0.1, 0.125 and 0.15 mg/kg SVP-Rapamycin, as well as both pegsiticase doses without SVP-Rapamycin...